Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Open Label Study of Afamelanotide (SCENESSE) in Xeroderma Pigmentosum
2019-000597-34Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jan 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in xeroderma pigmentosum (XP), sponsored by Clinuvel Pharmaceuticals. Primary endpoints: Change in UV-induced DNA damage and repair capacity and Safety and tolerability of afamelanotide. Started Jan 2021; status: completed.
02
Drugs
Afamelanotide
03
Conditions
xeroderma pigmentosum (XP)
Beyond the preview
Go deeper on 2019-000597-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000597-34.